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Abstract 
Background: Gene and chemical therapy has become one of the rising stars in the field of molecular medicine dur-
ing the last two decades. However, there are still numerous challenges in the development of efficient, targeted, and 
safe delivery systems that can avoid siRNA degradation and reduce the toxicity and adverse effects of chemotherapy 
medicine.
Results: In this paper, a highly efficient AS1411 aptamer modified, dsDNA and MMP-2 cleavable peptide-fabricated 
gold nanocage vehicle, which could load doxorubicin hydrochloride (DOX) and siRNAs to achieve a combination of 
tumor responsive genetic therapy, chemotherapy, and photothermal treatment is presented. Our results show that 
this combined treatment achieved targeted gene silencing and tumor inhibition. After nearly one month of treat-
ment with DOX-loaded Au-siRNA-PAA-AS1411 nanoparticles with one dose every three days in mice, a synergistic 
effect promoting the eradication of long-lived tumors was observed along with an increased survival rate of mice. The 
combined genetic, chemotherapeutic, and photothermal treatment group exhibited more than 90% tumor inhibition 
ratio (tumor signal) and a ~ 67% survival rate compared with a 30% tumor inhibition ratio and a 0% survival rate in the 
passive genetic treatment group.
Conclusions: The development of nanocarriers with double-stranded DNA and MMP-2 cleavable peptides provides 
a new strategy for the combined delivery of gene and chemotherapy medicine. Au-siRNA-PAA-AS1411 exerts high 
anticancer activities on lung cancer, indicating immense potentials for clinical application.
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Background
Lung cancer is one of the most common malignant 
tumors in the world. The five-year survival rate of 
patients with lung cancer remains very low due to dif-
ficulties of early diagnosis, drug resistance, and relapse 
after treatment. So far, surgical treatment is considered 
to be the only radical curative method, but most patients 
have reached the advanced stage by the time they seek 
treatment, and thus the optimal window for radical sur-
gery or radiotherapy is lost. New strategies are needed 
to improve the tolerability and efficacy of treatment for 
lung cancer. Gene therapy is an efficient and promising 
approach to treating malignant tumors by either degrad-
ing mRNAs or inhibiting their translation. Many siRNAs 
have been shown to be actively involved in metabolism, 
cell death, angiogenesis, metastasis and immunosuppres-
sion in cancer [1]. Using siRNAs as therapeutic agents 
for regulating cancer can alter the intrinsic properties of 
tumor cells and the tumor microenvironment. Increas-
ing attention has been focused on gene therapy due to its 
potential use in treating a variety of diseases, including 
cancers, by delivering genetic drugs to the target tumor 
sites [2–4]. Among various genetic drugs, the vascular 
endothelial growth factor (VEGF) family (VEGF A, B, C, 
D and Placenta growth factor) has been the most widely 
investigated [4–9]. The development of VEGF-targeted 
genetic drugs, including VEGF-A receptors, small mol-
ecule tyrosine kinase inhibitors and antibodies, has been 
widely investigated, and these drugs have been confirmed 
to be efficient anti-angiogenesis therapies [10–12]. How-
ever, naked siRNAs are difficult to use for in vivo appli-
cations, as they are easily degraded by serum nucleases 
and are rapidly eliminated through renal excretion. Also, 
to efficiently deliver to target sites, siRNAs should be 
considered in sufficient numbers. Therefore, a suitable 
gene delivery system that can protect nucleic acids from 
degradation and selectively deliver a sufficient amount of 
siRNAs to target sites is needed.
Nanoparticles (NPs) are effective carriers of multiple 
therapeutic and diagnostic agents [13–17]. Various meth-
ods have been reported for the modification of nanopar-
ticles to confer the NPs good bioavailability, low toxicity 
and a long circulation time [18–21]. NPs are now widely 
applied in oncology research for tumor imaging and 
theranostics [22–24]. NPs used for siRNA delivery have 
also been reported [25]. Chen et al. reported a magnetic 
mesoporous silica nanoparticle (M-MSN)-based siRNA 
delivery system for the delivery of VEGF-small inter-
fering RNA (siRNA) [5]. Ding et  al. reported polyethyl-
eneimine (PEI)-modified single-walled carbon nanotubes 
to deliver VEGF-targeted siRNA (siVEGF) for the syner-
gistic and targeted treatment of tumor angiogenesis [26]. 
James Finlay et al. synthesized polyethyleneimine-coated 
mesoporous silica nanoparticles (MSNs) for the deliv-
ery of siRNA, which led to a reduction in Twist1 [27]. 
However, these systems cannot protect the siRNA with 
a closed environment to avoid degradation. The amount 
of siRNAs delivered is also limited compared with the 
ratio of gene carries. In addition, a good vehicle should 
also have the ability to selectively transport oligonucleic 
acid-based therapeutics to the target sites and execute 
the controlled release the gene to the diseased tissue.
In the current study, a nanocage was designed for the 
co-delivery of gene and chemotherapy drugs. Au nano-
particles were selected as the vesicles due to their many 
promising characteristics, including controllable sizes 
and shapes, biocompatibility, nontoxicity, and ease of 
connecting with the target molecules due to the strong 
interactions with amine or thiol moieties. The distin-
guished X-ray attenuation property of Au nanoparticles 
enables these particles to serve as one of the most effec-
tive contrast agents for X-ray CT imaging. Besides, Au 
nanoparticles can absorb near-infrared laser frequencies 
to achieve thermal ablation of cancer cells [28–31]. Poly-
acrylic acid (PAA), a popularly used material, was used 
in this study to construct the surface of the cage by tak-
ing advantage of the numerous carboxylic acid groups 
available for biomolecule conjugation [32–35]. The 
strongly negative surface charge of PAA also conferred 
the Au nanocage good biocompatibility and water dis-
persity. Double-stranded DNA (dsDNA) molecules act 
as the rigid trestle in the gold nanocage structure. One 
single-stranded DNA molecule, ssDNA-2, was modified 
with thiol groups and anchored with the Au nanoparticle, 
and the complementary antisense strand, ssDNA-1, was 
modified with  NH2 and connected with PAA through 
an amidation reaction. In addition, PAA was divided 
into two groups and modified with two kinds of com-
plementary amino-modified oligonucleotides (ssDNA-3, 
ssDNA-4) and AS1411. ssDNA-2 was first anchored to 
the Au nanoparticle surface by the Au–S bond, and then 
the PAAs were modified with the complementary anti-
sense oligonucleotide, ssDNA-1, which was hybridized 
to ssDNA-2. The gold nanocages were closed through 
the complementary base pairing of DNA-3 and DNA-4 
with DNA-5 (linked with the MMP-2 cleavable peptide). 
Then, a large number of dsDNA molecules and peptides 
were stacked on the surface of the Au nanocages, render-
ing the Au nanoparticles as closed nanocages. To further 
enhance the antitumor efficacy, doxorubicin was intro-
duced into this nanocage system by taking advantage of 
the property that DOX can preferentially intercalate into 
double-stranded 5′-GC-3′ or 5′-CG-3′ to form a tightly 
coupled complex without chemical bond links [36]. The 
gold nanocages could selectively deliver the loading 
drugs and genes to the tumor sites due to modification 
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of AS1411, anti-nucleolin aptamers for site-specific tar-
geting against tumor cells, which overexpresses nucleolin 
receptors. The nanocages were destroyed by the matrix 
metalloproteinase (MMP)-2 enzymes, which were over-
expressed around the tumor tissues by the cleavage of the 
enzyme-cleavable peptide chain (contained in DNA-5) 
on the surface of the gold nanocages. Following the cleav-
age of the peptide chain, the tumor-targeted and con-
trolled drug release was achieved.
To our knowledge, this is the first proof of concept 
to construct a tumor responsive drug delivery nanoc-
age system using Au nanoparticle, dsDNA, and MMP-2 
cleavable peptide. The developed gold nanocage system 
shows good stability, excellent tumor inhibition ratio, and 
high gene delivery efficacy (Scheme 1).
Results and discussion
Au nanocage design and characterization
Citrate-coated gold nanoparticles of approximately 
10  nm were selected as the core of the nanocage and 
were synthesized according to a previously reported 
method [37]. The specific anti-VEGF siRNA duplex with 
the sequence of 5′-CCC ACA UAC ACA CAU AUA UUU-
3′ (sense) and 5′-UUG GGU GUA UGU GUG UAU AUA-3′ 
(antisense) was selected for the subsequent gene therapy, 
which has been certified to be one of the most efficient 
siRNA sequences [38]. PAA 2000 was selected for the 
nanocage construction and was divided into two groups. 
The first group, PAA-1, was modified with ssDNA-3 
(5′-AAA AGC GCG CGC GCGC-3′), ssDNA-1(AS1411 
aptamer). The second group, PAA-2, was modified with 
ssDNA-1(AS1411 aptamer) and ssDNA-4 (5′-CGC GCG 
CGC GCG AAAA-3′). AS1411 is an aptamer that targets 
nucleolin, which is abundant in the nucleus of normal 
cells but is also over expressed in the cell membrane of 
tumor cells, including prostate, lung, and breast cancers. 
The modification with AS1411 rendered the Au nanoc-
age capable of delivering therapeutic genes to lung cancer 
cells. The Au nanoparticles were first modified with thi-
olated-DNA-2 and thiolated anti-VEGF siRNA through 
Au-S bonds (DNA-2 : siRNA = 1:10 molar ratio), then 
reacted with equal molar ratios of modified PAA-1 and 
PAA-2. The DNA braiding structure on the surface of 
sphere is shown in Fig. 1.
To avoid linking multiple gold nanoparticles on same 
PAA chain, a low concentration of ssDNA-2-modified 
gold nanoparticle was used. The dynamic light scattering 
(DLS) (Figure S2) and TEM images (Fig. 2) showed that 
the Au nanocage were stable and well dispersed. The aver-
age diameter of the Au core was approximately ~ 10 nm. 
The mean particle diameter of the Au nanocage was 
approximately 16  nm with an approximately 3-nm shell 
thickness. The UV-Vis of the Au-siRNA and Au modi-
fied with ss-DNA exhibited a 5 nm and 3 nm wavelength 
shift, respectively, compared with the Au nanoparticles, 
showed that DNAs had successfully been modified on the 
surface of gold nanoparticles (Fig. 2d).
To evaluate the stability of the Au nanocages in 
serum, the in  vitro release of siRNAs from the Au 
nanocages was investigated. In this experiment, siRNAs 
were modified with Cy5. The Au nanocages were incu-
bated in cell culture medium containing 10% serum for 
up to 72  h. During the first 8 h, approximately 3% of 
the siRNAs were released. The cumulative release of the 
siRNA increased to 8% during the first 24 h. The total 
release of siRNA reached 16% and 48% in the following 
48 and 72 h, respectively. Considering the antitumor 
efficiency of the Au nanocage, Doxorubicin hydrochlo-
ride (DOX) was also loaded into the gold nanocage in 
the last step of the Au nanocage construction according 
to the mechanism that DOX can preferentially inter-
calate into double-stranded -GC- base pairs to form 
a tightly coupled complex. The DOX release behavior 
was also investigated in cell culture medium containing 
10% serum for up to 72 h. In the first 8 h, the cumula-
tive release of DOX was controlled to within 1%, and 
then the release increased to 5% at the 24-h time point. 
The total amount of DOX release was within 7% for 
up to 72 h incubation, which effectively avoid the drug 
leakage on the way of distributing to the tumor sites 
(Fig. 3a). In order to study the release behavior of DOX 
from the gold nanocage at tumor microenvironment, 
the DOX release behavior at different pH solution were 
investigated and were shown in Additional file  1: Fig-
ure S3. The cumulative release of DOX was up to 28% at 
24-h time point.
In vitro targeting and anti‑tumor effect of gold nanocages
The lung cancer cell line NCI-H889, which was gener-
ated from disseminated cancer cells from a KPT mouse, 
were selected for the in  vitro investigation of the cellu-
lar uptake and antitumor efficiency of the Au nanoc-
ages. The ultrastructural TEM images revealed that the 
Au-dsDNA-PAA-AS1411 nanoparticles were swallowed 
by the NCI-H889 cells and were mainly concentrated in 
the endosomes or lysosomes (Fig. 3c, d). Confocal images 
of Au nanocages with and without the AS1411 aptamer 
modification revealed that both Au-siRNA-PAA-AS1411 
and Au-siRNA-PAA could enter the NCI-H889 lung can-
cer cells. The apparent uptake of Au-siRNA-PAA-AS1411 
was observed after 1 h of incubation. The uptake of Au-
siRNA-PAA was less efficient than that of Au-siRNA-
PAA-AS1411 at same incubation time, as evidenced by 
the weaker fluorescence intensity (Fig. 4a, b). The VEGF 
silencing efficiency of both Au-siRNA-PAA-AS1411 and 
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Au-siRNA-PAA was evaluated in NCI-H889 lung cancer 
cells. Both Au-siRNA-PAA-AS1411 and Au-siRNA-PAA 
exhibited an apparent gene silencing efficiency in a dose-
dependent manner. A gene silencing efficacy as high as 
80% was observed for the Au-siRNA-PAA-AS1411 group 
at the mRNA level by qPCR at a dose of 10  nM gold 
nanocages up to 48 h of incubation (Fig. 3b). The VEGF 
gene silencing efficiency tends to be stable when the 
concentration of Au-siRNA-PAA-AS1411 higher than 
10  nM. The antitumor efficacy of the Au-siRNA-PAA-
AS1411 nanocages was also evaluated by flow cytometry 
analysis (Fig.  4c). Annexin V-FITC/Propidium Iodide 
double-staining was used to determine the apoptosis rate 
of NCI-H889 cells induced by siRNA or siRNA combined 
with the chemotherapy drug and laser irradiation. The 
cells were divided into five groups, namely, the control 
group, the siRNA group, the Au-siRNA-PAA group and 
the Au-siRNA-PAA-AS1411 group. For the siRNA group, 
the cells were incubated with siRNA and treated with 
gene therapy only; for the Au-siRNA-PAA group, the 
cells were incubated with DOX-loaded Au-siRNA-PAA 
nanocages and treated with the combination of gene and 
chemotherapy therapy; for the Au-siRNA-PAA-AS1411 
group, the cells were incubated with DOX-loaded Au-
siRNA-PAA-AS1411 nanocages and target-treated with 
gene therapy, chemotherapy and laser irradiation; for 
the Au-siRNA-PAA-AS1411(no DOX) group, cells were 
incubated with Au-siRNA-PAA-AS1411 without DOX 
loading and targeted treated with the combination of 
siRNA and thermotherapy. The untreated cells served 
as the control group. Maximal apoptosis and necrosis 
were observed in the Au-siRNA-PAA-AS1411 group, 
with subpopulations exhibiting as much as 49.46% early 
apoptosis and 37.51% late apoptosis. The cell apoptosis 
level decreased to 68.97% for the Au-siRNA-PAA group; 
however, both of these groups exhibited much higher cell 
apoptosis levels compared to the siRNA group.
In vivo targeting and anti‑tumor effect of gold nanocages
Next, Au-siRNA-PAA-AS1411 was investigated for its 
ability to deliver anti-VEGF siRNA to a lung cancer 
orthotopic murine model of BALB/c nude mice express-
ing NCI-H889 lung cancer cells. To avoid the nonspe-
cific uptake of the antitumor drugs, a complex system 
Scheme 1 The schematic illustration of the construction of gold nanocages and the tumor-induced gene- and DOX-releasing mechanism. 
Gold nanoparticles were first decorated with thiolated-DNA-2 and thiolated anti-VEGF siRNAs based on the thiol-Au bond. PAA-1 was modified 
with ssDNA-1, ssDNA-3, and the AS1411 aptamer. PAA-2 was modified with ssDNA-1, ssDNA-4, and the AS1411 aptamer; then, the ssDNA-2 and 
siRNA-conjugated (DNA-2: siRNA = 1:10 molar ratio) gold nanoparticles were conjugated with equal molar ratios of PAA-1, PAA-2, and DNA-5 to 
generate the rigid trestle of the gold nanocages. The gold nanocage were finally closed through the complementary base pairing of DNA-3 and 
DNA-4 with DNA-5
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which allows for the inhalation-mediated local delivery 
of an anticancer drug was employed to administer the 
Au-siRNA-PAA/ Au-siRNA-PAA-AS1411 nanocages to 
the lung tumors. In  vivo biodistribution imaging stud-
ies were applied for the investigation of the tumor-tar-
geting ability of Au-siRNA-PAA-AS1411. BALB/c nude 
mice bearing NCI-H889 lung tumors were treated with 
1 mL of 800 µg  mL− 1 Au-siRNA-PAA-AS1411 and Au-
siRNA-PAA through inhalation-mediated local delivery. 
In vivo imaging was performed over a time-course from 1 
to 24 h. As shown in Fig. 5, the Au-siRNA-PAA-AS1411 
nanocages were randomly concentrated at the lung site at 
1 h post-delivery. At the 4-hr time point, the fluorescence 
signal from the gold nanocages became decreased and 
more concentrated toward the tumor signal; thereafter, 
until 16 hrs, the gold nanocage signal exhibited a great 
degree of overlay with tumor signal. The signal lasted 
up to 24 h at the lung tumor site. The quantitative bio-
distribution of Au-siRNA-PAA-AS1411 gold nanocages 
was also investigated by isolated organ imaging and ROI 
(region of interest) analysis of the mean organ fluores-
cence intensity (Fig. 5b, d, e). The results showed that the 
Au-siRNA-PAA-AS1411 gold nanocages could target the 
lung tumor, and moreover, they exhibited a long reten-
tion time. The fluorescence intensity of the Au-siRNA-
PAA-AS1411 gold nanocages on the lung (tumor) was 
much stronger compared with other organs. A lower 
mean fluorescence intensity was also observed for the 
Au-siRNA-PAA group (Fig. 5b). The fluorescence signal 
from the Au-siRNA-PAA-AS1411 gold nanocages at the 
Fig. 1 The DNA braiding process and the structure of the Au nanocage






























Fig. 2 TEM images and UV-vis absorption spectrum of gold nanoparticles. a TEM images of ~ 10-nm citrate-coated gold nanoparticles; b Low 
magnification TEM images of Au-siRNA-PAA-AS1411 nanocages; c TEM images of Au-siRNA-PAA-AS1411 nanocages with negative staining; d 
Changes in the UV-Vis absorption spectrum of citrate-coated gold nanoparticles, Au-ssDNA and Au-dsDNA; The UV-Vis of the Au-dsDNA and 
Au-ssDNA (DNA-2 : siRNA = 1:10 molar ratio) exhibited a 5 nm and 3 nm wavelength shift, respectively, compared with the Au nanoparticles, 
showing the successful modification of DNAs on the surface of gold nanoparticles. e The gel image of Au, Au-siRNA, and siRNA showing the 
successful coating of siRNAs. The band of siRNA located at a molecular weight lower than that of Au-siRNA indicates that siRNAs were successfully 
conjugated on the surface of Au nanoparticles
Fig. 3 In vitro siRNA / drug release, gene silence efficacy and ultrastructural TEM images of lung tumor tissue from treated mice. a siRNA 
release from the Au-siRNA-PAA-AS1411 nanocages and Au-siRNA; DOX release from Au-siRNA-PAA-AS1411 nanocages; b The silencing effect 
of Au-siRNA-PAA-AS1411 and Au-siRNA-PAA in the lung-adenocarcinoma NCI-H889 cell line. The gene silencing efficacy reached 80% for the 
Au-siRNA-PAA-AS1411 group with a concentration of 10 nM Au-siRNA-PAA-AS1411 and up to 48 h of incubation (n = 3, ***P < 0.005); c, d TEM 
images of NCI-H889 cells incubated with 500 µg  mL− 1 Au-siRNA-PAA-AS1411 nanocages
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lung (tumor) organ exhibited a high degree of overlay 
with the lung tumor signal (Fig. 5f ). Similarly, inductively 
coupled plasma mass spectrometry (ICP-MS) revealed 
that after 7 days of treatment with the Au-siRNA-PAA-
AS1411 nanocages, both Au-siRNA-PAA and Au-siRNA-
PAA-AS1411 almost exclusively accumulated in the lung 
tissue (Fig.  5c). As much as an ~ 12-fold increase was 
observed for the Au-siRNA-PAA-AS1411-treated group 
compared with other organs. The Au-siRNA-PAA group 
also exhibited an accumulation of the nanoparticle signal, 
but it was much lower compared with the Au-siRNA-
PAA-AS1411 group, with an approximate 6-fold increase 
compared with other organs. Only minimal accumulation 
was observed in other organs. These findings indicate 
that Au-siRNA-PAA-AS1411 targeted and accumulate 
in the tumor-bearing lung after the inhalation-mediated 
local delivery, and minimal Au-siRNA-PAA-AS1411 
nanocages diffused to other organs from the lung.
Drug and gene loading gold nanocages inhibited lung 
cancer growth and prolonged the survival of mice
Having established that the Au-siRNA-PAA-AS1411 
nanocage could selectively deliver siRNA and DOX to the 
tumor sites, we next evaluated the lung tumor inhibition 
ratio using NCI-H889 lung tumor-bearing mice treated 
with Au-siRNA-PAA-AS1411(no DOX), Au-siRNA-PAA 
and Au-siRNA-PAA-AS1411 loaded with DOX. To cre-
ate an orthotopic murine model of lung cancer, NCI-
H889 lung cancer cells were injected subcutaneously into 
the lungs of nude mice. Accordingly, BALB/c nude mice 
bearing NCI-H889 lung tumors were treated with DOX-
loaded Au-siRNA-PAA-AS1411 gold nanocages at a dose 
of 1 mL (800 µg  mL− 1 ) and administered on days 12, 15, 
18, 21, 24, 27, 30, 33 and 36 (Au-siRNA-PAA-AS1411 
group). Considering the side effect of the drugs, 808-nm 
laser irradiation was performed 4 h after the inhalation 
administration at a power density of 1 W  cm− 2 for 5 min. 
Fig. 4 Confocal images and cell apoptosis levels of NCI-H889 cells incubated with the Au-siRNA-PAA-AS1411 /Au-siRNA-PAA nanocages. a 
NCI-H889 cells incubated with 100 µg  mL− 1 Au-siRNA-PAA-AS1411 for 1 h; b NCI-H889 cells incubated with 100 µg  mL− 1 Au-siRNA-PAA for 1 h. 
Chanel 1: Fluorescence signal of Au nanocages modified with Cy5; Chanel 2: Hoechst 33,342 signal; Chanel 3: Bright field; Chanel 4: Overlapped 
field. Magnification: ×40; c Flow cytometric analysis of NCI-H889 cell apoptosis induced by siRNA, Au-siRNA-PAA and Au-siRNA-PAA-AS1411 with 
the MMP-2 enzyme at 37 °C for 24 h
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Three control groups of mice were treated as follows: (a) 
the siRNA group, in which mice were administered with 
siRNA and treated through gene therapy only; (b) the 
Au-siRNA-PAA group, in which mice were administered 
with DOX-loaded Au-siRNA-PAA nanocages and pas-
sively treated with the combination of siRNA and chemo-
therapy; and (c) the Au-siRNA-PAA-AS1411(no DOX) 
group, in which mice were administered with Au-siRNA-
PAA-AS1411 without DOX loading and targeted treated 
with the combination of siRNA and thermotherapy. For 
the thermotherapy therapy groups, the surface tempera-
ture of the lungs was increased to 48 ℃ after the laser 
irradiation. The tumor inhibition ratio was calculated 
using a live animal imaging system to monitor the tdTo-
mato-labeled NCI-H889 lung tumor fluorescence (Fig. 6). 
Compared to the siRNA groups, tumor-bearing mice 
subjected to targeted treatment with the combination of 
gene therapy, chemotherapy and photothermal therapy 
exhibited the best tumor inhibition ratio, with nearly 
complete tumor regression after 36 days of treatment. 
More than a three-fold decrease in tdTomato signal was 
observed after 18 days of treatment compared with the 
siRNA group. In comparison, the Au-siRNA-PAA and 
Au-siRNA-PAA-AS1411 (no DOX) groups also exhibited 
a good tumor inhibition ratio after 18 days of treatment. 
The total fluorescence intensity of the Au-siRNA-PAA 
and Au-siRNA-PAA-AS1411 (no DOX) groups were 
stronger than that of the Au-siRNA-PAA-AS1411 group 
after 36 days of treatment, which exhibited relative 
weaker tumor inhibition efficiency. The Au-siRNA-PAA-
AS1411, Au-siRNA-PAA-AS1411 (no DOX) and siRNA-
siRNA-PAA groups exhibited a stronger tumor inhibition 
effect when compared with the siRNA group, as no mice 
survived after 28 days of treatment with passive targeted 
gene therapy only. Accordingly, the BALB/c nude mice 
bearing NCI-H889 lung-adenocarcinoma tumors treated 
with DOX-loaded Au-siRNA-PAA-AS1411 nanocages 
exhibited the highest survival rate when the VEGF pro-
tein was knocked down in combination with chemo-
therapy and photothermal therapy (Fig. 6c). In summary, 
these findings indicate that a combination of gene ther-
apy, chemotherapy and photothermal therapy is far more 
efficient for tumor inhibition compared with only silenc-
ing VEGF using gold nanocages via passive targeting.
  The safety of all formulations of gold nanocages was 
evaluated by monitoring the body weight of the mice. As 
shown in Fig. 6b, a small decrease in body weight occurred 
during the first 7 days of administration. However, no sig-
nificant body weight fluctuation was observed in the fol-
lowing days, suggesting that the gold nanocage doses used 
Fig. 5 The ability of gold nanocages to deliver anti-VEGF siRNA to the lung cancer orthotopic murine model of BALB/c nude mice expressing 
NCI-H889 lung cancer cells. a Representative noninvasive imagings of NCI-H889 tumor-bearing nude mice in vivo (inhalation-mediated local 
delivery of 1 mL 800 µg  mL− 1 Au-siRNA-PAA/Au-siRNA-PAA-AS1411 gold nanocages); (b) Quantitative biodistribution of self-assembled 
nanoparticles in lung tumors and organs based on the ROI (region of interest) analysis of the mean fluorescence intensity of each organ; c 
Quantification of Au accumulated in organs by ICP-MS. The data of Au-siRNA-PAA-AS1411 and Au-siRNA-PAA distribution in liver, spleen, lung 
(tumor), kidney and heart at 7 days after the inhalation-mediated local delivery of gold nanocages. The data in b and c are expressed as the 
mean ± SD (n = 6, ***P < 0.005) in each study group; d The bright field organ imaging of Au-siRNA-PAA-AS1411-treated mice; e The in vitro organ 
imaging of Au-siRNA-PAA-AS1411-treated mice; f Representative NCI-H889 lung-adenocarcinoma cells fluorescence and Au nanocage fluorescence 
analysis of ex vivo lungs from Au-siRNA-PAA-AS1411-treated mice
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in the experiments were within the safe range. A steady 
increase in weight was observed in the Au-siRNA-PAA, 
Au-siRNA-PAA-AS1411(no DOX) and Au-siRNA-PAA-
AS1411 groups, much better than that of the siRNA group, 
which was treated via passive targeted genetic therapy 
only. The siRNA group exhibited a sharp decline in body 
weight after 15 days of treatment, and no mice survived 
after 36 days of treatment.(Fig. 6c) These findings confirm 
that the combination of gene therapy, chemotherapy and 
photothermal therapy is far more efficient than genetic 
therapy only, and the combination therapy prolonged the 
lives of the mice and improved their health to some extent.
The VEGF silencing effect, antitumor efficacy, and the 
potential toxicity of the gold nanocages were also evalu-
ated by immunohistochemistry and hematoxylin and 
eosin (H&E) staining (Fig.  7). Immunohistochemical 
staining for VEGF in the lung (tumor) tissue revealed 
an ~ 70% reduction in VEGF for the mice treated with 
Au-siRNA-PAA-AS1411(DOX), which showed a more 
significant reduction compared to the mice treated with 
Au-siRNA-PAA-AS1411(no DOX) and Au-siRNA-PAA 
(Fig.  7a). A clear difference in lung tumor morphology 
between the siRNA and Au-siRNA-PAA-AS1411 groups 
was observed in the H&E-stained tissues (Fig. 7b). More 
tumor foci were seen in the siRNA group. These results 
indicate that the number of tumor cells was decreased in 
the mice treated with the DOX-loaded Au-siRNA-PAA-
AS1411 nanoparticles through combined multimodal 
therapy. To further prove the safety of the gold nanoc-
ages, tissue sections from Au-siRNA-PAA-AS1411-
treated mouse organs were examined to evaluate the 
potential toxicities. The morphologies of the organs 
of the treated mice, as shown in Fig. 7c, were similar to 
those of organs from the untreated healthy mice. Myo-
cardial revealed no myocardial inflammation or necrosis. 
The liver cells were arranged in order, and no liver cell 
degeneration, necrosis, or hepatic periportal inflamma-
tory cell infiltration was observed. The glomerulus and 
tiny tubules of the kidney were normal, with no hyaline 
change or any necrotic area. Overall, these findings con-
firmed the good tumor inhibition effect of the combined 
treatment by Au-siRNA-PAA-AS1411 nanoparticles, and 
no significant toxicity was evident in mice treated with 
DOX-loaded Au-siRNA-PAA-AS1411 nanocages.






















Fig. 6 Lung cancer inhibition ratio and the survival rate of the mice. a Representative non-invasive imagings of lung-adenocarcinoma NCI-H889 
tumor-bearing nude mice treated with siRNA, Au-siRNA-PAA, Au-siRNA-PAA-AS1411(no DOX) and Au-siRNA-PAA-AS1411 nanocages at days 7, 18 
and 36; b Body weight change curve of tumor-bearing mice over the 36 days of treatment. c Kaplan–Meier survival curves of mice treated with 
siRNA (green), DOX-loaded Au-siRNA-PAA (black), DOX-loaded Au-siRNA-PAA-AS1411 (red) and Au-siRNA-PAA-AS1411 without DOX(blue). Data 
represent the mean ± standard deviation (n = 6, ***P < 0.005)
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Conclusions
Gene therapy is an efficient and promising approach to 
treat malignant tumors by either degrading mRNAs or 
inhibiting their translation. To address the problems of 
the degradation of siRNA in serum, the rapid elimination 
by renal excretion, and the delivery of sufficient amounts 
of siRNA to target the tumor site, we developed a new 
gold nanocage vehicle for the delivery of large amounts 
of siRNA. To maximize the treatment effect, DOX was 
loaded into the nanocage and released in a controlled 
manner at the tumor sites together with the siRNAs. 
Genetic, chemotherapeutic and photothermal combined 
targeted treatment was realized with the surface modi-
fication with the AS1411 aptamer. To avoid degradation 
and nonspecific uptake and to maximize the therapeutic 
effect on lung tumors, the aerosol inhalation method was 
applied for the in vivo experiments. Our results exhibited 
that targeted silencing combined with chemo and photo-
thermal therapy can inhibit tumor progression and pro-
mote increased survival in mice.
This study is the first attempt to construct a nanocage 
for siRNA delivery and achieve the controlled release of 
siRNA and drugs by taking advantage of MMP-2 cleava-
ble peptide. Any kind of siRNA used for lung tumor inhi-
bition could be loaded, and the siRNA sequence could 
also be replaced with other sequences of siRNA that are 
more efficient for lung cancer or treating other diseases. 
In addition, gold nanoparticles exhibited to be an excel-
lent X-ray contrast agent due to their high X-ray attenu-
ation and nontoxicity, which facilitated a more accurate 
visualization of the controlled target drug release. We 
expect that this new kind of drug and gene vehicle will be 
the basis for more efficient therapeutics for treating lung 
cancer. A similar strategy could be applied to treat other 




The Anti-VEGF antibody was purchased from abcam. 
DNAs and siRNAs were purchased from Sangon Bio-
tech (Shanghai) and Jinweizhi Company. DOX were pur-
chased from Aladdin Company (Shanghai, China).
Synthesis and characterization of gold nanoparticles
The 10-nm gold nanoparticles were synthesized by 
first dissolving  HAuCl4 (1  mL, 1% w/v) in Nanopure™ 
 H2O water (100  mL) with magnetic stirring, heating 
until reflux, then subsequently adding 1 mL trisodium 
citrate (3% w/v). Heating was continued for 7  min, at 
which time the reaction bottle was immediately placed 
on ice without stirring. The resulting solution of gold 
nanoparticles was used without further purification 
for later experiments. Based on the TEM analysis, the 
average particle size was approximately 10  nm. The 
concentration of the AuNPs was analyzed by UV-vis 
absorbance spectroscopy and calculated according to 
the following formula: A = εlc (A is the absorbance, ε 
is the molar absorption coefficient, l is the thickness of 
the liquid layer, and c is the liquid concentration). The ε 
is 1.37*108 M− 1cm− 1 for λ = 523 nm of 10 nm Au nan-
oparticle [39].
Surface functionalization of AuNPs
The gold nanoparticles used for oligonucleotide con-
jugation were first treated with bis(p-sulfonatophenyl)
phenylphosphine dihydrate dipotassium salt (BSPP), 
and then 300  nM gold nanoparticles was incubated 
with 800-fold of thiolated DNA-2 and siRNA (DNA-
2:siRNA = 1:10 molar ratio) in 0.5x TBE for more than 12 
hrs. Next, 5 M NaCl was added in six increments to bring 
the final concentration to 300  mM, and aliquots were 
taken every 2 to 3 hrs. Centrifugation (8,000  rpm for 
40 min) was applied to get rid of the salt and free DNA. 
Finally, the UV-Vis of the final AuNPs was measured to 
calculate the molar concentration.
Gold nanocage construction
PAA functionalization with oligonucleotides was per-
formed by carbodiimide chemistry assisted by N-hydrox-
ysuccinimide (EDC/NHS coupling reaction) between 
the carboxylated PAA and the primary amine groups of 
the oligonucleotides. PAA-1 was conjugated with 5-fold 
molar ratios of DNA-1, DNA-3 and the AS1411 aptamer. 
The resultant products were purified by dialysis for 72 
hrs. PAA-2 was conjugated with 5-fold molar ratios of 
DNA-1, DNA-4 and the AS1411 aptamer. 20 nM DNA-2 
oligonucleotide functionalized gold nanoparticles were 
incubated with 100  nM PAA-1, PAA-2 and 150  nM 
ssDNA-5 in 0.5x TBE overnight. The final gold nanocages 
were purified by centrifugation at 10,000×g for 30 min in 
0.5 × TBE 2 to 3 times. To determine the average size, 
particle distribution and morphology of the gold nanoc-
ages, samples were analyzed through DLS and field emis-
sion TEM (JEM-2100F). 1 mg  mL− 1 uranyl acetate was 
selected for negative staining. The gold nanocage solu-
tion was dripped onto a carbon film-supported copper 
mesh and allowed to air dry before being subjected to 
TEM observation.
DOX loading in the Au‑siRNA‑PAA‑AS1411 nanocage
To investigate the amount of DOX loading in the DNA 
nanostructure, 5  µM Au-siRNA-PAA-AS1411 nanoc-
age was incubated with DOX (1  mM) in 10  mM PBS 
(pH 7.4) for 24 hr. Then centrifuge, test the concen-
tration of DOX in the supernatant. The molar ratio of 
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Au-siRNA-PAA-AS1411: DOX was 1:50.5 and this ratio 
was utilized in the subsequent experiments.
In vitro siRNA/drug release from the gold nanocages
A dialysis method was employed to investigate the release 
behavior of siRNA and DOX from the gold nanocages. 
First, 3 mL of gold nanocage was transferred into a dial-
ysis bag with 18,000 MWCO. The dialysis bag was then 
dipped into a 50-mL cell culture medium containing 10% 
serum and incubated at 37 °C with continuous stirring at 
200 rpm for as long as 72 h. The, 0.3 mL of the external 
cell culture medium was removed for analysis at prede-
termined time intervals, and an equal volume of dialysis 
solution was replenished. The amount of Cy5 modified 
siRNA released was quantified by measuring the fluores-
cence signal of Cy5. The DOX concentration was meas-
ured by HPLC.
Cell culture
The lung-adenocarcinoma NCI-H889 cell line was 
selected for the in  vitro targeting and cell apoptosis 
experiments. The lung-adenocarcinoma NCI-H889 cell 
line was cultured in DMEM with 10% heat inactivated 
fetal bovine serum (Gibco), 100 units of potassium peni-
cillin and 100 µg of streptomycin sulfate per 1 mL of cul-
ture media at 37 °C in 5%  CO2.
Fig. 7 Histology and Immunohistochemistry of mice tissues treated with gold nanocages. a Immunohistochemical analysis of VEGF in lung tissue. 
~70% reduction of VEGF expression was observed in the lungs treated with Au-siRNA-PAA-AS1411; VEGF (red chanel); Nuclei (blue chanel); b 
Histological analysis of lung tissue treated with Au-siRNA-PAA-AS1411(DOX) compared with the control groups of lung tissue treated with siRNA 
and DOX-loaded Au-siRNA-PAA; c H&E-stained tissue sections from mice subjected to inhalation-mediated local treatment with DOX-loaded 
Au-siRNA-PAA-AS1411 and PBS for 36 days. Scale bars: 50 µm
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Cellular uptake and distribution of self‑assembled 
nanodrugs
The lung-adenocarcinoma NCI-H889 cells were seeded 
onto 28-mm glass cover slips for 24 h before being incu-
bated with the gold nanocages. Then, the cells were 
incubated with 100  µg  mL− 1 Au-siRNA-PAA-AS1411 /
Au-siRNA-PAA nanocages at 37 °C for 1 h, then washed 
twice with PBS and fixed with a 4% paraformaldehyde 
solution for 30  min at room temperature. The nuclei 
were then stained with Hoechst 33,342 (10 µg  mL− 1) at 
37 °C for 15 min, and the slides were rinsed three times 
with PBS. A confocal laser scanning microscope (CLSM) 
(Leica TCS SP8, Germany) was used to detect the cellular 
uptake and distribution of gold nanocages in the NCI-
H889 cells. To visualize the cellular distribution of gold 
nanocages via TEM, NCI-H889 lung-adenocarcinoma 
cells were incubated with 500 µg mL-1 Au-siRNA-PAA-
AS1411 nanocages for up to 48  h and then fixed with 
glutaraldehyde (2.5%) for more than 1 h. Then, the sam-
ples were sent to Shanghai Normal University for TEM 
testing.
In vivo targeted delivery of gold nanocages
Lung-adenocarcinoma NCI-H889 cells were selected 
to construct the lung cancer orthotopic murine model. 
The lung cancer orthotopic murine model was estab-
lished by subcutaneously injecting NCI-H889 cells into 
the lungs of six-week-old BALB/c nude mice after mak-
ing a 0.5 cm cut under the front leg of mice. Six BALB/c 
nude mice bearing NCI-H889 lung tumors in each group 
were injected with 1  mL 800  µg  mL− 1 Au-siRNA-PAA-
AS1411 and Au-siRNA-PAA gold nanoparticles through 
the inhalation-mediated local delivery method. The fluo-
rescence distribution was monitored at 1 h, 4 h, 16 h and 
24 h using a small animal in vivo imaging system with the 
appropriate wavelengths. The mice used for the in vitro 
organ imaging were killed 4 h after the gold nanocages 
were administered. All animal experiment was author-
ized according to the Shanghai Jiao Tong University Ani-
mal Care guidelines.
Tumor inhibition activity of gold nanocages
BALB/c nude mice bearing the NCI-H889 orthotopic 
murine model of lung cancer were treated with Au-
siRNA-PAA-AS1411 gold nanocages on days 12, 15, 18, 
21, 24, 27, 30, 33, and 36. Considering the wastage in the 
course of inhalation administration, 1  mL 800  µg  mL− 1 
Au-siRNA-PAA-AS1411 gold nanocages were used. 
Then, 808-nm laser irradiation was performed after 4 
h of the inhalation administration at a power density of 
1  W  cm− 2 for 5  min. Three groups of orthotopic lung 
tumor-bearing mice treated with siRNA, DOX-loaded 
Au-siRNA-PAA and Au-siRNA-PAA-AS1411 (no DOX) 
were used as the control. All experiments included six 
mice per treatment group unless otherwise noted.
Quantitative PCR
Total RNA from lung-adenocarcinoma NCI-H889 cells 
and from tissues from tumor-bearing mice was extracted 
using the RNeasy Plus Mini Kit according to the manu-
facture’s protocol. qRT-PCR was performed with the 
SuperScript™ III One-Step RT-PCR System with the 
Platinum™ Taq DNA Polymerase Kit. The samples were 
placed in the preheated thermal cycler, which was pro-
grammed with the following thermal cycling procedure: 
45 ~ 60  °C for 30  min; 2  min at 94  °C; 40 cycles 15  s at 
94  °C, 30  s at 55 ~ 66  °C, 1 min at 68  °C; finally, 1 cycle 
5 min at 68 °C. GAPDH was used as the reference gene.
Histology and immunohistochemistry
Freshly removed lung tumor tissues and other organs 
were rinsed with sterile PBS, frozen with liquid nitro-
gen and sectioned with a cryostat microtome. For the 
immunohistochemical analysis, lung (tumor) sections 
were first fixed with 4% paraformaldehyde for 15 min, 
then treated with 0.25% TritonX-100 for 10  min and 
washed with PBS three times. Next, the tissues were 
blocked in PBST containing 1% BSA for 30  min and 
then washed with PBS 3 times. Then, the tissue was 
incubated with an anti-VEGF antibody for 1 h at room 
temperature and then washed three times with PBS. 
Then, the tissues were incubated with the secondary 
antibody (Alexa Fluor 532 goat anti-mouse IgG, 1:250, 
Invitrogen) for 1  h at room temperature and subse-
quently washed 3 times with PBS. The nuclei were then 
stained with Hoechst 33,342 (10 µg  mL− 1) at 37 °C for 
15 min and then rinsed three times with PBS. For H&E 
staining, the organs were cut into small pieces and 
fixed with 4% paraformaldehyde, embedded in paraf-
fin, sectioned and stained according to the standard 
procedures. All tissues were harvest alter 36 days treat-
ment except the siRNA group, which were harvest after 
28 days treatment. All slices were examined by CLSM 
(Leica TCS SP8, Germany).
Statistical analysis
Data are presented as the mean ± SD unless other-
wise indicated. Differences between groups were 
examined using Student’s t-test. Statistically signifi-
cant P values were indicated in figures or captions as 
***P < 0.005; **P < 0.01; *P < 0.05. All in  vivo experi-
ments used six mice per treatment group unless noted 
otherwise.
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